Weiss Ratings Reaffirms “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating restated by stock analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

Several other research firms also recently commented on FDMT. Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. Royal Bank of Canada dropped their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, January 13th. Leerink Partners lowered their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. Finally, BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $40.00 to $15.00 in a report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and an average target price of $38.56.

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $4.58 on Friday. The company’s fifty day moving average price is $6.66 and its 200-day moving average price is $11.49. 4D Molecular Therapeutics has a one year low of $4.50 and a one year high of $36.25. The company has a market capitalization of $211.73 million, a PE ratio of -1.61 and a beta of 2.81.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. increased its stake in 4D Molecular Therapeutics by 238.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock worth $16,684,000 after buying an additional 1,087,147 shares during the period. Braidwell LP increased its position in shares of 4D Molecular Therapeutics by 231.7% during the third quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after acquiring an additional 855,990 shares during the period. Redmile Group LLC raised its stake in shares of 4D Molecular Therapeutics by 17.6% during the third quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock valued at $13,643,000 after acquiring an additional 188,655 shares in the last quarter. Novo Holdings A S boosted its holdings in shares of 4D Molecular Therapeutics by 7.1% in the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $16,215,000 after purchasing an additional 100,000 shares during the period. Finally, Squarepoint Ops LLC boosted its holdings in shares of 4D Molecular Therapeutics by 652.7% in the second quarter. Squarepoint Ops LLC now owns 110,041 shares of the company’s stock valued at $2,310,000 after purchasing an additional 95,422 shares during the period. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.